Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 7/20 | 0.40 |
| ▸ | JAK1 | P23458 | 6/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | CDK8 | P49336 | 9/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.37 |
| ▸ | CCNC | P24863 | 7/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963244 | 0.89 | OTUD7B (0.38) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL18592722 | 0.89 | OTUD7B (0.53) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL23513705 | 0.86 | OTUD7B (0.45) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL24716916 | 0.83 | OTUD7B (0.45) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL16559765 | 0.83 | CYP2D6 (0.38) | OTUD7BCYP2D6 | |
| SCHEMBL20243884 | 0.80 | OTUD7B (0.41) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL23103171 | 0.80 | OTUD7B (0.46) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL23107538 | 0.80 | OTUD7B (0.46) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL16750021 | 0.80 | OTUD7B (0.46) | OTUD7BTYK2JAK1JAK2JAK3 | |
| SCHEMBL13703126 | 0.79 | OTUD7B (0.45) | OTUD7BTYK2JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067661-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-02-29 | — | — | US | disclosed |
| US-20240067661-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-02-29 | — | — | US | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11780854-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-10-10 | — | — | US | disclosed |
| US-11780854-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-10-10 | — | — | US | disclosed |
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| US-20130244996-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067661-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN2, EGLN3, EGLN1 | OTUD7B 1784/4885TYK2 3175/4885JAK1 2183/4885 |
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | OTUD7B 813/4885TYK2 4393/4885JAK1 2739/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | OTUD7B 3851/4885TYK2 3327/4885JAK1 2664/4885 |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTC4S | OTUD7B 3447/4885TYK2 2363/4885JAK1 1511/4885 |
| US-20130244996-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTC4S | OTUD7B 3447/4885TYK2 2363/4885JAK1 1511/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | OTUD7B 2935/4885TYK2 1967/4885JAK1 1872/4885 |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | OTUD7B 994/4885TYK2 4482/4885JAK1 3308/4885 |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | OTUD7B 3124/4885TYK2 1666/4885JAK1 1076/4885 |
| US-11780854-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN2, EGLN3, EGLN1 | OTUD7B 1784/4885TYK2 3175/4885JAK1 2183/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | OTUD7B 2500/4885TYK2 1989/4885JAK1 733/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | OTUD7B 4102/4885TYK2 2409/4885JAK1 735/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | OTUD7B 143/4885TYK2 4425/4885JAK1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.